Somers EC, Marder W, Cagnoli P, Lewis EE, DeGuire P, Gordon C, et al. Population-based incidence and prevalence of systemic lupus erythematosus。the Michigan lupus epidemiology and surveillance program. Arthritis Rheum. 2014;66:369–78. https://doi.org/10.1002/art.38238/abstract.
Article
Google Scholar
Li M, Zhang W, Leng X, Li Z, Ye Z, Li C, et al. Chinese sle treatment and research group (cstar) registry: I. Major clinical characteristics of chinese patients with systemic lupus erythematosus. Lupus. 2013;22:1192–9.
Article
CAS
PubMed
Google Scholar
Urowitz MB, Gladman DD, Tom BD, Ibanez D, Farewell VT. Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus. J Rheumatol. 2008;35:2152–8. https://doi.org/10.3899/jrheum.080214.
Article
PubMed
Google Scholar
Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006;54:2550–7. https://doi.org/10.1002/art.21955.
Article
CAS
PubMed
Google Scholar
Pettersson T, Pukkala E, Teppo L, Friman C. Increased risk of cancer in patients with systemic lupus erythematosus. Ann Rheum Dis. 1992;51:437–9. https://doi.org/10.1136/ard.51.4.437.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bernatsky S, Boivin JF, Joseph L, Rajan R, Zoma A, Manzi S, et al. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum. 2005;52:1481–90. https://doi.org/10.1002/art.21029.
Article
CAS
PubMed
Google Scholar
Parikh-Patel A, White RH, Allen M, Cress R. Cancer risk in a cohort of patients with systemic lupus erythematosus (sle) in california. Cancer Causes Control. 2008;19:887–94. https://doi.org/10.1007/s10552-008-9151-8.
Article
PubMed
PubMed Central
Google Scholar
Ladouceur A, Clarke AE, Ramsey-Goldman R, Bernatsky S. Malignancies in systemic lupus erythematosus: An update. Curr Opin Rheumatol. 2019;31:678–81. https://doi.org/10.1097/BOR.0000000000000648.
Article
CAS
PubMed
Google Scholar
Guo JY, Ren ZG, Xuan YY, Li TF, Liu XJ, Niu CZ, et al. Clinical characteristics and risk factors of patients with systemic lupus erythematosus and cancer. Zhonghua Nei Ke Za Zhi. 2020;59:218–21. https://doi.org/10.3760/cma.j.issn.0578-1426.2020.03.009.
Article
CAS
PubMed
Google Scholar
Bjornaîdal L, Lofstrom B, Yin L, Lundberg IE, Ekbom A. Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosu. Lupus. 2002;31:66–71.
Google Scholar
Tarr T, Gyorfy B, Szekanecz E, Bhattoa HP, Zeher M, Azegedi G, et al. Occurrence of malignancies in Hungarian patients with systemic lupus erythematosus: Results from a single center. Ann N Y Acad Sci. 2007;1108:76–82. https://doi.org/10.1196/annals.1422.008.
Article
PubMed
Google Scholar
Smedby KE, Hjalgrim H, Askling J, Chang ET, Gregersen H, Porwit-MacDonald A, et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst. 2006;98:51–60. https://doi.org/10.1093/jnci/djj004.
Article
PubMed
Google Scholar
Chen YJ, Chang YT, Wang CB, Wu CY. Malignancy in systemic lupus erythematosus: A nationwide cohort study in taiwan. Am J Med. 2010;123(1150):e1–6. https://doi.org/10.1016/j.amjmed.2010.08.006.
Article
Google Scholar
Cao L, Tong H, Xu G, Liu P, Meng H, Wang J, et al. Systemic lupus erythematous and malignancy risk: a meta-analysis. PLoS One. 2015;10:e0122964. https://doi.org/10.1371/journal.pone.0122964.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sultan SM, Ioannou Y, Isenberg DA. Is there an association of malignancy with sle?an analysis of 276 patients under longterm review. Rheumatology. 2000;39:1147–52.
Article
CAS
PubMed
Google Scholar
Cibere J, Sibley J, Haga M. Systemic lupus erythematosus and the risk of malignancy. Lupus. 2001;10:394–400. https://doi.org/10.1191/096120301678646128.
Article
CAS
PubMed
Google Scholar
Nived O, Bengtsson A, JoÈnsen A, Sturfelt G, Olsson H. Malignancies during follow-up in an epidemiologically defined systemic lupus erythematosus inception cohort in southern sweden. Lupus. 2001;10(500-4). https://doi.org/10.1191/096120301678416079.
Lin YC, Yen JH, Chang SJ, Lin YC. The age-risk relationship of haematologic malignancies in female patients with systemic lupus erythematosus: a nationwide retrospective cohort study. Lupus. 2012;21:1250–6. https://doi.org/10.1177/0961203312451783.
Article
PubMed
Google Scholar
Tallbacka KR, Pettersson T, Pukkala E. Increased incidence of cancer in systemic lupus erythematosus: A Finnish cohort study with more than 25 years of follow-up. Scand J Rheumatol. 2018;47:461–4. https://doi.org/10.1080/03009742.2017.1384054.
Article
CAS
PubMed
Google Scholar
Apor E, O’Brien J, Stephen M, Castillo JJ. Systemic lupus erythematosus is associated with increased incidence of hematologic malignancies: a meta-analysis of prospective cohort studies. Leuk Res. 2014;38:1067–71. https://doi.org/10.1016/j.leukres.2014.06.025.
Article
PubMed
Google Scholar
Hemminki K, Huang W, Sundquist J, Sundquist K, Ji J. Autoimmune diseases and hematological malignancies: exploring the underlying mechanisms from epidemiological evidence. Semin Cancer Biol. 2020;64:114–21. https://doi.org/10.1016/j.semcancer.2019.06.005.
Article
CAS
PubMed
Google Scholar
Moss KE, Ioannou Y, Sultan SM, Haq I, Isenberg DA. Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades. Ann Rheum Dis. 2002;61:409–13.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bernatsky S, Ramsey-Goldman R, Joseph L, Boivin J-F, Costenbader KH, Urowitz MB, et al. Lymphoma risk in systemic lupus: effects of disease activity versus treatment. Ann Rheum Dis. 2014;73:138–42. https://doi.org/10.1136/annrheumdis-2012-202099.
Article
CAS
PubMed
Google Scholar
Boddu PC, Zeidan AM. Myeloid disorders after autoimmune disease. Best Pract Res Clin Haematol. 2019;32:74–88. https://doi.org/10.1016/j.beha.2019.02.002.
Article
PubMed
PubMed Central
Google Scholar
Kiss E, Kovacs L, Szodoray P. Malignancies in systemic lupus erythematosus. Autoimmun Rev. 2010;9:195–9. https://doi.org/10.1016/j.autrev.2009.07.004.
Article
CAS
PubMed
Google Scholar
Bernatsky S, Clarke A, Ramsey-Goldman R. Malignancy and systemic lupus erythematosus. Curr Rheumatol Rep. 2002;4:351–8. https://doi.org/10.1007/s11926-002-0045-6.
Article
PubMed
Google Scholar
Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases_ a meta-analysis. Arch Intern Med. 2005;165:2337–44.
Article
PubMed
Google Scholar
Ehrenfeld M, Abu-Shakra M, Buskila D, Shoenfeld Y. The dual association between lymphoma and autoimmunity. Blood Cells Mol Dis. 2001;27:750–6. https://doi.org/10.1006/bcmd.2001.0442.
Article
CAS
PubMed
Google Scholar
Lofstrom B, Backlin C, Sundstrom C, Ekbom A, Lundberg IE. A closer look at non-Hodgkin’s lymphoma cases in a national Swedish systemic lupus erythematosus cohort: a nested case-control study. Ann Rheum Dis. 2007;66:1627–32. https://doi.org/10.1136/ard.2006.067108.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hansen A, Lipsky PE, Dorner T. B-cell lymphoproliferation in chronic inflammatory rheumatic diseases. Nat Clin Pract Rheumatol. 2007;3:561–9. https://doi.org/10.1038/ncprheum0620.
Article
CAS
PubMed
Google Scholar
Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725–34. https://doi.org/10.1002/art.1700400928.
Article
CAS
PubMed
Google Scholar
Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64:2677–86. https://doi.org/10.1002/art.34473.
Article
PubMed
PubMed Central
Google Scholar
Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood. 2009;114:937–51. https://doi.org/10.1182/blood-2009-03-209262.
Article
CAS
PubMed
Google Scholar
Jaffe ES. The 2008 who classification of lymphomas: implications for clinical practice and translational research. American Society of. Hematology. 2009:523–31.
Arber DA. The 2016 who classification of acute myeloid leukemia: what the practicing clinician needs to know. Semin Hematol. 2019;56:90–5. https://doi.org/10.1053/j.seminhematol.2018.08.002.
Article
PubMed
Google Scholar
Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29:288–91.
PubMed
Google Scholar
Chen W, Sun K, Zheng R, Zeng H, Zhang S, Xia C, et al. Cancer incidence and mortality in china, 2014. Chin J Cancer Res. 2018;30:1–12. https://doi.org/10.21147/j.issn.1000-9604.2018.01.01.
Article
PubMed
PubMed Central
Google Scholar
Bernatsky S, Ramsey-Goldman R, Labrecque J, Joseph L, Boivin JF, Petri M, et al. Cancer risk in systemic lupus: an updated International Multi-Centre Cohort Study. J Autoimmun. 2013;42:130–5. https://doi.org/10.1016/j.jaut.2012.12.009.
Article
PubMed
PubMed Central
Google Scholar
Zhang S, Ye Z, Li C, Li Z, Li X, Wu L, et al. Chinese systemic lupus erythematosus treatment and research group (cstar) registry xi_ gender impact on long-term outcomes. Lupus. 2019;0:1–7. https://doi.org/10.1177/0961203319839845.
Article
Google Scholar
Ekstrom Smedby K, Vajdic CM, Falster M, Engels EA, Martinez-Maza O, Turner J, et al. Autoimmune disorders and risk of non-hodgkin lymphoma subtypes: a pooled analysis within the interlymph consortium. Blood. 2008;111:4029–38. https://doi.org/10.1182/blood-2007-10-119974.
Article
CAS
PubMed
PubMed Central
Google Scholar
Danza A, Ruiz-Irastorza G. Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies. Lupus. 2013;22:1286–94.
Article
CAS
PubMed
Google Scholar
JohnsonID DK, Reynolds KM, PooleID BD, MontierthID MD, ToddID VM, Barnado A, et al. Contribution of viral infection to risk for cancer in systemic lupus erythematosus and multiple sclerosis. PLoS One. 2021;16:e0243150. https://doi.org/10.1371/journal.pone.0243150.
Article
CAS
Google Scholar
Szabo MZ, Szodoray P, Kiss E. Dyslipidemia in systemic lupus erythematosus. Immunol Res. 2017;65:543–50. https://doi.org/10.1007/s12026-016-8892-9.
Article
CAS
PubMed
Google Scholar
Atta AM, Silva J, Santiago MB, Oliveira IS, Oliveira RC, Sousa Atta MLB. Clinical and laboratory aspects of dyslipidemia in brazilian women with systemic lupus erythematosus. Clin Rheumatol. 2018;37:1539–46. https://doi.org/10.1007/s10067-018-4051-0.
Article
PubMed
Google Scholar
Urowitz M, Gladman D, Ibañez D, Fortin P, Sanchez-Guerrero J, Bae S, et al. Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort. Lupus. 2007;16:731–5. https://doi.org/10.1177/0961203307081113.
Article
CAS
PubMed
Google Scholar
Boretti A. Nutrition, lipidic parameters, and cancer risk and progress. Nutrition. 2020;69:110538. https://doi.org/10.1016/j.nut.2019.06.019.
Article
CAS
PubMed
Google Scholar
Vlagea A, Falagan S, Gutierrez-Gutierrez G, Moreno-Rubio J, Merino M, Zambrana F, et al. Antinuclear antibodies and cancer: a literature review. Crit Rev Oncol Hematol. 2018;127:42–9. https://doi.org/10.1016/j.critrevonc.2018.05.002.
Article
PubMed
Google Scholar
Lü S, Zhang J-P, Wu H-S, Zheng X-J, Chu Y-W, Xiong S-D. Anti-tumor effect of anti-dsdna autoantibodies. Chin J Oncol. 2005;27:73–6.
Google Scholar
Hansen JE, Chan G, Liu Y, Hegan DC, Dalal S, Dray E, et al. Targeting cancer with a lupus autoantibody. Sci Transl Med. 2012;4.
Engels EA, Cerhan JR, Linet MS, Cozen W, Colt JS, Davis S, et al. Immune-related conditions and immune-modulating medications as risk factors for non-Hodgkin’s lymphoma: a case-control study. Am J Epidemiol. 2005;162:1153–61. https://doi.org/10.1093/aje/kwi341.
Article
PubMed
Google Scholar
Hsu CY, Lin MS, Su YJ, Cheng TT, Lin YS, Chen YC, et al. Cumulative immunosuppressant exposure is associated with diversified cancer risk among 14 832 patients with systemic lupus erythematosus: a nested case-control study. Rheumatology (Oxford). 2017;56:620–8. https://doi.org/10.1093/rheumatology/kew457.
Article
Google Scholar
Ertz-Archambault N, Kosiorek H, Taylor GE, Keleme K, Dueck A, Castro J, et al. Association of therapy for autoimmune disease with myelodysplastic syndromes and acute myeloid leukemia. JAMA Oncol. 2017;3:936–43. https://doi.org/10.1001/jamaoncol.2016.6435.
Article
PubMed
PubMed Central
Google Scholar
Ruiz-Irastorza G, Ugarte A, Egurbide MV, Garmendia M, Pijoan JI, Martinez-Berriotxoa A, et al. Antimalarials may influence the risk of malignancy in systemic lupus erythematosus. Ann Rheum Dis. 2007;66:815–7. https://doi.org/10.1136/ard.2006.067777.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hsu CY, Lin YS, Cheng TT, Syu YJ, Lin MS, Lin HF, et al. Adherence to hydroxychloroquine improves long-term survival of patients with systemic lupus erythematosus. Rheumatology (Oxford). 2018;57:1743–51. https://doi.org/10.1093/rheumatology/key167.
Article
CAS
Google Scholar